122243-36-1

Upstream product

• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 711-38-6 4'-methoxy-2,2,2-trifluoroacetophenone 

Downstream Products

• 120039-66-9 Toluene-4-sulfonic acid 1-(3-cyano-4-methoxy-phenyl)-2,2,2-trifluoro-ethyl ester 
• 122242-89-1 Toluene-4-sulfonic acid 1-(3-cyano-4-methoxy-phenyl)-2,2,2-trifluoro-1-methyl-ethyl ester 
• 122243-23-6 2-Methoxy-5-(2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl)-benzonitrile 
• 303143-11-5 C₁₉H₁₇BrF₃NO₆S 
• 303143-14-8 2-[2-bromo-4-(3-trifluoromethyl-diaziridin-3-yl)-phenoxy]-acetamide 
• 303143-07-9 [2-Bromo-4-(2,2,2-trifluoro-acetyl)-phenoxy]-acetic acid ethyl ester 
• 303143-05-7 1-(3-bromo-4-hydroxyphenyl)-2,2,2-trifluoroethanone 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.]

Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors

We have previously reported the discovery of a new class of potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) derived from benzylidene oxazolidinedione and thiazolidinedione scaffolds. In this study, these analogs were designed, synthesized, and evaluated in a human cell-based assay. The detailed structure-activity relationship (SAR) surrounding this pharmacophore were developed, and consequently a number of compounds from this series demonstrated single-digit nanomolar 17β-HDS3 inhibitory activity in vitro. Subsequent optimization work in pursuit of the improvement of oral bioavailability demonstrated in vivo proof-of-concept by prodrug strategy based on phosphate esters for these 17β-HSD3 inhibitors. When a phosphate ester 16 was administered orally at a high dose of 100 mg/kg, 16 showed approximately two times more potent testosterone (T)-lowering effect against a positive control in the luteinizing hormone-releasing hormone (LH-RH)-induced T production assay. The T-lowering effect continued at ca 10% level of control over 4 h after administration. The nonsteroidal molecules based on this series have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer.

Synthesis of novel phenoxy-linked diazirine glycero- and sphingolipid probes via trialkylaryltin intermediates

Two photoaffinity lipid probes, phosphatidylcholine analog 1 and ceramide analog 2, were synthesized via trialkylaryltin intermediates 10b,b' using a Stille coupling strategy. The latter are stable for months at -20°C. Iododestannylation afforded lipid probes 1 and 2. (C) 2000 Elsevier Science Ltd.